Fig. 5
From: The Rac inhibitor HV-107 as a potential therapeutic for metastatic breast cancer
HV-107 at 1000 nM impact Rac-related GTPases and PAK1/2 effectors on breast cancer cells. Triple negative breast cancer cells MDA-MB-231 and MDA-MB-468 were subjected to HV-107 treatment at various concentrations (ranging from 0 to 2000 nM) for a duration of 24 h. GTP-bound Cdc42 (A, B) and GTP-bound Rho (C, D) were assessed using the Cdc42 GLISA and Rho GLISA assays, respectively. In panels E and L, western blot images depict the expression of total and phosphorylated PAK1 and PAK2 in MDA-MB-231 and MDA-MB-468 cells treated with HV-107. The quantification of total PAK1 and PAK2 (F, I, M, and P) and phosphorylated PAK1 (Thr 423) and PAK2 (Thr 402) (G, J, N, and Q) are shown. The ratios of phosphorylated PAK1 and PAK2 to total PAK levels are displayed in panels H, K, O, and R. N = 4. Error bars represent ± SEM; * p ≤ 0.05